No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018

OTTAWA, ONTARIO–(Marketwired – April 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors

OTTAWA, ONTARIO–(Marketwired – April 10, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study

1st Canadian Cannabis Smokable Pellet Study 1st Step Towards Pharmaceutical Distribution of Cannabis OTTAWA, ONTARIO–(Marketwired – April 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Names Guy Chamberland as Interim CEO

OTTAWA, ONTARIO–(Marketwired – April 3, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.

OTTAWA, ONTARIO–(Marketwired – March 19, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction“) […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome

TTAWA, ONTARIO–(Marketwired – March 14, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Signs Co-development and Distribution Partnership Term Sheet

OTTAWA, ONTARIO–(Marketwired – March 8, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has signed a co-development and distribution partnership […]

No Picture
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Takes First Steps into European Medical Cannabis Market

OTTAWA, ONTARIO–(Marketwired – March 6, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF) announced today that its partner PS Innovations will be seeking CE Marking for its Rx Princeps™ Inhalation Device, thereby opening the […]